NARDO, ANTONELLA
 Distribuzione geografica
Continente #
AS - Asia 80
NA - Nord America 80
EU - Europa 65
SA - Sud America 22
AF - Africa 13
Totale 260
Nazione #
US - Stati Uniti d'America 75
IT - Italia 52
SG - Singapore 38
CN - Cina 26
BR - Brasile 19
CI - Costa d'Avorio 11
KR - Corea 8
FI - Finlandia 5
IE - Irlanda 4
IN - India 3
MX - Messico 3
CA - Canada 2
BD - Bangladesh 1
BE - Belgio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DE - Germania 1
EC - Ecuador 1
GB - Regno Unito 1
IQ - Iraq 1
OM - Oman 1
PK - Pakistan 1
SC - Seychelles 1
SN - Senegal 1
VE - Venezuela 1
VN - Vietnam 1
Totale 260
Città #
Santa Clara 35
Singapore 29
Hefei 15
Chicago 14
Abidjan 11
Civitanova Marche 8
Seoul 8
Milan 7
Ashburn 5
Boardman 5
Catania 4
Dublin 4
Mexico City 3
Rome 3
Tremestieri Etneo 3
Chennai 2
Florence 2
Helsinki 2
Lappeenranta 2
Los Angeles 2
Palermo 2
Baghdad 1
Barueri 1
Brasília 1
Bronte 1
Brussels 1
Buffalo 1
Campinas 1
Campos do Jordão 1
Can Tho 1
Caucaia 1
Chongqing 1
Curitiba 1
Dakar 1
Dalian 1
Dallas 1
Extrema 1
Fazenda Rio Grande 1
Fort St. James 1
Genoa 1
Guayaquil 1
Itaberaba 1
Itaquaquecetuba 1
Lahore 1
Langfang 1
Linyi 1
London 1
Mariana 1
Messina 1
Munich 1
Naples 1
New York 1
Newmarket 1
Olomouc 1
Passa e Fica 1
Pirenópolis 1
Rancagua 1
Registro 1
Rio de Janeiro 1
Santa Maria 1
Santos 1
Seeb 1
São Paulo 1
Sítio Novo do Tocantins 1
Turku 1
Valencia 1
Washington 1
Totale 212
Nome #
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 53
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 48
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 42
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 39
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 37
Emergencies in Hematology: Why, When and How I Treat? 22
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 15
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 13
Totale 269
Categoria #
all - tutte 1.408
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.408


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202317 0 0 0 0 0 0 4 2 4 0 7 0
2023/202456 0 4 2 9 0 14 10 1 0 3 12 1
2024/2025183 1 24 5 14 25 26 8 5 12 15 25 23
2025/202613 13 0 0 0 0 0 0 0 0 0 0 0
Totale 269